These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 24211510)

  • 1. A randomized controlled trial of platelet activity before and after cessation of clopidogrel therapy in patients with stable cardiovascular disease.
    Ford I; Scott NW; Herd V; Mitchell LR; Williams DJ; Brittenden J
    J Am Coll Cardiol; 2014 Jan; 63(3):233-9. PubMed ID: 24211510
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Doubling the clopidogrel dose in patients with reduced responsiveness to the standard dose is associated with a limited effectiveness as evaluated by impedance aggregometry.
    Stellbaum C; Ayral Y; Morguet A; Schultheiss HP; Rauch U
    Cardiovasc Revasc Med; 2012; 13(3):159-66. PubMed ID: 22503564
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A single-centre, randomised study on platelet reactivity after abrupt or gradual discontinuation of long-term clopidogrel therapy in patients after percutaneous coronary intervention.
    Nadrowski P; Syzdół M; Wańha W; Nabiałek E; Skrzypek M; Góral J; Siewniak M; Kozakiewicz K; Ochała A; Tendera M; Wojakowski W
    Kardiol Pol; 2016; 74(7):634-43. PubMed ID: 26779855
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evidence of platelet sensitization to ADP following discontinuation of clopidogrel therapy in patients with stable coronary artery disease.
    Lordkipanidzé M; Diodati JG; Schampaert E; Palisaitis DA; Pharand C
    Platelets; 2015; 26(6):545-51. PubMed ID: 25167467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of reloading to overcome clopidogrel nonresponsiveness in patients with acute myocardial infarction.
    Matetzky S; Fefer P; Shenkman B; Varon D; Savion N; Hod H
    Am J Cardiol; 2008 Sep; 102(5):524-9. PubMed ID: 18721506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ADP-induced platelet aggregation frequently fails to detect impaired clopidogrel-responsiveness in patients with coronary artery disease compared to a P2Y12-specific assay.
    Schäfer A; Weinberger S; Flierl U; Eigenthaler M; Störk S; Walter U; Ertl G; Bauersachs J
    Thromb Haemost; 2008 Oct; 100(4):618-25. PubMed ID: 18841284
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A double-blind, randomized study on prevention and existence of a rebound phenomenon of platelets after cessation of clopidogrel treatment.
    Sibbing D; Stegherr J; Braun S; Mehilli J; Schulz S; Seyfarth M; Kastrati A; von Beckerath N; Schömig A
    J Am Coll Cardiol; 2010 Feb; 55(6):558-65. PubMed ID: 20152561
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How to optimise clopidogrel therapy? Reducing the low-response incidence by aggregometry-guided therapy modification.
    Neubauer H; Lask S; Engelhardt A; Mügge A
    Thromb Haemost; 2008 Feb; 99(2):357-62. PubMed ID: 18278186
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loading with 600 mg clopidogrel in patients with coronary artery disease with and without chronic clopidogrel therapy.
    Kastrati A; von Beckerath N; Joost A; Pogatsa-Murray G; Gorchakova O; Schömig A
    Circulation; 2004 Oct; 110(14):1916-9. PubMed ID: 15262828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between inflammatory biomarkers and platelet aggregation in patients under chronic clopidogrel treatment.
    Bernlochner I; Steinhubl S; Braun S; Morath T; Jaitner J; Stegherr J; Mehilli J; von Beckerath N; Schömig A; Kastrati A; Sibbing D
    Thromb Haemost; 2010 Dec; 104(6):1193-200. PubMed ID: 20838744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Justification of 150 mg clopidogrel in patients with high on-clopidogrel platelet reactivity.
    Aradi D; Rideg O; Vorobcsuk A; Magyarlaki T; Magyari B; Kónyi A; Pintér T; Horváth IG; Komócsi A
    Eur J Clin Invest; 2012 Apr; 42(4):384-92. PubMed ID: 21902692
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clopidogrel but not aspirin reduces P-selectin expression and formation of platelet-leukocyte aggregates in patients with atherosclerotic vascular disease.
    Klinkhardt U; Bauersachs R; Adams J; Graff J; Lindhoff-Last E; Harder S
    Clin Pharmacol Ther; 2003 Mar; 73(3):232-41. PubMed ID: 12621388
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monitoring platelet inhibition after clopidogrel with the VerifyNow-P2Y12(R) rapid analyzer: the VERIfy Thrombosis risk ASsessment (VERITAS) study.
    Malinin A; Pokov A; Spergling M; Defranco A; Schwartz K; Schwartz D; Mahmud E; Atar D; Serebruany V
    Thromb Res; 2007; 119(3):277-84. PubMed ID: 16563469
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The additive antiplatelet action of clopidogrel in patients with coronary artery disease treated with aspirin.
    Dropinski J; Jakiela B; Sanak M; Wegrzyn W; Biernat M; Dziedzina S; Plutecka H; Szczeklik A
    Thromb Haemost; 2007 Jul; 98(1):201-9. PubMed ID: 17598014
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stenting.
    Cuisset T; Frere C; Quilici J; Morange PE; Nait-Saidi L; Carvajal J; Lehmann A; Lambert M; Bonnet JL; Alessi MC
    J Am Coll Cardiol; 2006 Oct; 48(7):1339-45. PubMed ID: 17010792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of clopidogrel, aspirin and both antiplatelet drugs on platelet function in patients with peripheral arterial disease.
    Jagroop IA; Matsagas MI; Geroulakos G; Mikhailidis DP
    Platelets; 2004 Mar; 15(2):117-25. PubMed ID: 15154604
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adding cilostazol to dual antiplatelet therapy achieves greater platelet inhibition than high maintenance dose clopidogrel in patients with acute myocardial infarction: Results of the adjunctive cilostazol versus high maintenance dose clopidogrel in patients with AMI (ACCEL-AMI) study.
    Jeong YH; Hwang JY; Kim IS; Park Y; Hwang SJ; Lee SW; Kwak CH; Park SW
    Circ Cardiovasc Interv; 2010 Feb; 3(1):17-26. PubMed ID: 20118150
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is a 300 mg clopidogrel loading dose sufficient to inhibit platelet function early after coronary stenting? A platelet function profile study.
    Angiolillo DJ; Fernandez-Ortiz A; Bernardo E; Ramírez C; Sabaté M; Hernández-Antolín R; Moreno R; Escaned J; Alfonso F; Bañuelos C; Macaya C
    J Invasive Cardiol; 2004 Jun; 16(6):325-9. PubMed ID: 15156004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of platelet alpha2-adrenergic receptor activity in stable coronary artery disease patients on dual antiplatelet therapy.
    Béres BJ; Tóth-Zsámboki E; Vargová K; László A; Masszi T; Kerecsen G; Préda I; Kiss RG
    Thromb Haemost; 2008 Nov; 100(5):829-38. PubMed ID: 18989527
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of reticulated platelets and platelet size heterogeneity on platelet activity after dual antiplatelet therapy with aspirin and clopidogrel in patients with stable coronary artery disease.
    Guthikonda S; Alviar CL; Vaduganathan M; Arikan M; Tellez A; DeLao T; Granada JF; Dong JF; Kleiman NS; Lev EI
    J Am Coll Cardiol; 2008 Aug; 52(9):743-9. PubMed ID: 18718422
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.